Correction to “Stimulation of P2 purinergic receptors induces the release of eosinophil cationic protein and interleukin-8 from human eosinophils”

IF 7.5 2区医学 Q1 PHARMACOLOGY & PHARMACY

British Journal of Pharmacology Pub Date : 2026-10-09 Epub Date: 2026-08-23 DOI:10.1111/bph.70665

引用次数: 0

Abstract

Idzko, M., Panther, E., Bremer, H.C., Sorichter, S., Luttmann, W., Virchow, J.C., Di Virgilio, F., Herouy, Y., Norgauer, J. and Ferrari, D. (2003), Stimulation of P2 purinergic receptors induces the release of eosinophil cationic protein and interleukin-8 from human eosinophils. British Journal of Pharmacology, 138: 1244–1250. https://doi.org/10.1038/sj.bjp.0705145

The sixth author's name is incorrect. The correct name is J. Christian Virchow.

The online version of this article has been corrected accordingly.

We apologize for this error.

查看原文本刊更多论文

更正“刺激P2嘌呤能受体诱导人嗜酸性粒细胞释放嗜酸性阳离子蛋白和白细胞介素-8”。

Idzko， M., Panther， E., Bremer， H.C, Sorichter， S., Luttmann， W., Virchow， J.C, Di Virgilio， F., Herouy， Y., Norgauer， J.和Ferrari， D.(2003)，刺激P2嘌呤能受体诱导嗜酸性粒细胞阳离子蛋白和白细胞介素-8的释放。中国药理学杂志，38(3):1244-1250。https://doi.org/10.1038/sj.bjp.0705145The第六作者的名字不正确。正确的名字是j·克里斯蒂安·维尔肖。本文的在线版本已进行了相应的更正。我们为这个错误道歉。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

British Journal of Pharmacology 医学-药学

CiteScore

15.40

自引率

12.30%

发文量

270

审稿时长

2.0 months

期刊介绍： The British Journal of Pharmacology (BJP) is a biomedical science journal offering comprehensive international coverage of experimental and translational pharmacology. It publishes original research, authoritative reviews, mini reviews, systematic reviews, meta-analyses, databases, letters to the Editor, and commentaries. Review articles, databases, systematic reviews, and meta-analyses are typically commissioned, but unsolicited contributions are also considered, either as standalone papers or part of themed issues. In addition to basic science research, BJP features translational pharmacology research, including proof-of-concept and early mechanistic studies in humans. While it generally does not publish first-in-man phase I studies or phase IIb, III, or IV studies, exceptions may be made under certain circumstances, particularly if results are combined with preclinical studies.